Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust.
A medical device maker selling more and earning a third less has a cost problem rather than a demand problem. Hospitals do not stop buying syringes and catheters because the economy turns. Whatever changed here happened inside the company, which is usually the more fixable kind of trouble.
BDX ranks 8th among the 10 Best Blue Chip Dividend Stocks to Buy Right Now. To see which stocks outranked it, click HERE.
The Cash Did Not Fall the Way the Profit Did:
Becton Dickinson reports two different free cash flow figures, and only one of them answers the question most readers are asking. The levered measure is struck after debt service. The cash flow statement figure is operating cash flow less capital spending, and that is the one that tells you whether the business converts profit into money. On that basis, the conversion is healthy and comfortably exceeds reported net income, despite earnings falling 34.30%.
The cash did not drop the way the profit did, which is the single strongest argument for patience here. The demand side is also intact, because revenue grew 5.40% and hospital consumables are about as predictable a revenue stream as healthcare offers, with procedure volumes moving on reimbursement rather than the economy. The dividend is covered by that cash and consumes a manageable share of earnings, which is the only test that matters for the aristocrats whose payouts have never been cut.
DON’T MISS: 14 Best Pharma Dividend Stocks to Buy in 2026
The Financing Is What Changed:
Gross margin is ordinary for devices sold into hospitals. The operating line is where research, the sales force, and the amortisation of past acquisitions land.
Net margin then falls to 4.19%, and that final step is the one that moved. Interest on $16.81 billion of debt sits in that gap against a cash balance under a billion. A current ratio of 0.87 means short-term obligations exceed short-term assets, which describes a balance sheet with no spare room at a company that has spent years acquiring.
The forward multiple of 13.81 sits far below the trailing one of 31.58 and expects earnings per share to roughly triple, to $13.30. That is a very large recovery to price in advance, and it assumes the cost base comes down rather than the revenue going up. Device makers and drugmakers are sold on the same recovery promise, and one group has the longer record, which is the argument for the drugmakers on our 2026 dividend list. The one we rated highest there has added 13% since.
Hospital budgets are also under genuine pressure, which limits how much of that recovery Becton Dickinson actually controls. Pricing a tripling of earnings in advance leaves nothing in reserve for the day it slips.
The Valuation Case:
The verdict is that Becton Dickinson looks reasonably valued on cash and expensive on reported earnings, and the gap between those two views is the entire investment case. What you are paying for is a cost problem being fixed at a company whose demand was never in doubt. That is a more tractable problem than most, and it is not free at this price. Buying the business before the recovery is priced in is the whole game, and that window has largely closed here. That said, it is still open across the quality companies priced below their worth.
Conclusion:
Demand was never the problem here. Revenue grew, and the cash flow statement shows a conversion comfortably above reported net income. However, net margin fell to low single digits because interest on a heavy debt load sits between the operating line and the bottom line. Short-term obligations exceed short-term assets, and the forward multiple assumes earnings per share roughly triples. Watch net margin. That is where the debt is being paid for.
Market Sentiment:
Becton, Dickinson and Company was held by 46 hedge funds with a combined stake value of about $2.18 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 48 hedge fund holders with a cumulative investment value of around $1.65 billion in the previous quarter.
While we acknowledge the risk and potential of BDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 14 Best Pharma Dividend Stocks to Buy in 2026 and 10 Best Dividend Aristocrat Stocks to Buy in 2026
This article is originally published at Insider Monkey.
Hedge Fund Resource Center